Laboratory Corporation of America (LabCorp) has launched an expanded testing menu to help clinicians diagnose, treat and monitor the course of inflammatory bowel disease (IBD).
The menu comprises IBD Expanded Profile that includes ulcerative colitis and Crohn's disease-specific antibody markers that improve diagnostic sensitivity and provide valuable prognostic information regarding the severity of disease.
The company said for patients diagnosed with IBD, TPMT Enzyme Activity assay can be utilized prior to thiopurine drug treatment to assess dosing levels and potential adverse drug reaction.
The thiopurine Metabolites test also helps physicians to optimize ongoing dosing to reach and maintain therapeutic goals and avoid possible drug toxicity.
LabCorp chief medical officer Mark Brecher said, "These enhancements to LabCorp's IBD test menu are adjuncts to its broader offering of digestive disease testing that includes cost-efficient cascade testing to help physicians diagnose Irritable Bowel Syndrome and non-Celiac Gluten Sensitivity."
LabCorp also offers testing for patients treated with new biological drugs like infliximab that allow physicians to monitor drug concentration levels and assess the impact of anti-infliximab antibody levels on drug efficacy.
